Provectus Pharmatech, Inc.;The Rockefeller University
发明人:
KRUEGER, James G.,GARCET, Sandra,SINGER, Jamie,WACHTER, Eric
申请号：
AU2018375425
公开号：
AU2018375425A2
申请日:
2018.11.29
申请国别(地区):
AU
年份:
2020
代理人:
摘要：
A treatment for inflammatory dermatoses, such as psoriasis and atopic dermatitis (eczema), is disclosed that utilizes topical administration of a halogenated xanthene, such as rose bengal, together with administration of one or more complementary targeted systemic dermatology therapies, preferably a therapy that addresses the inflammatory pathway and is other than an NSAID that is a COX-1 and/or COX-2 inhibitor. Examples of complementary targeted systemic therapeutic ingredients include: corticosteroids, including betamethasone dipropionate and fluocinonide； dithranol； vitamin D analogs, including calcipotriol； and retinoids, non-biologics including methotrexate, ciclosporin, hydroxycarbamide, and fumarates including dimethyl fumarate； as well as one or more biologies, including antibodies or paratope-containing antibody portions to TNF-a, antibodies to pro-inflammatory cytokines interleukin-12, interleukin-23 and interleukin-17, and TNF inhibitors. Treatment of other epithelial tissue, such as the lining of the gut, is also disclosed.
